KRAS and neoplasm: Additionally, this combined strategy induced tumor shrinkage in various KRAS-mutant NSCLC xenograft models (G12C, G12S, and Q61H) as well as in various KRAS-mutant NSCLC patients (G12D, G12F, G12S, G12V, and Q61H).